- Home
- RNP vs ESPR Comparison
RNP vs ESPR Comparison
Compare RNP & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNP | ESPR |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.7M | 898.5M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | RNP | ESPR |
|---|---|---|
| Price | $19.94 | $3.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.67 |
| AVG Volume (30 Days) | 117.6K | ★ 5.0M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 7.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $303,802,000.00 |
| Revenue This Year | N/A | $26.11 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.83 |
| 52 Week Low | $15.52 | $0.69 |
| 52 Week High | $21.27 | $4.13 |
Technical Indicators
Market Signals| Indicator | RNP | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 49.95 |
| Support Level | $19.36 | $3.87 |
| Resistance Level | $20.10 | $4.05 |
| Average True Range (ATR) | 0.23 | 0.19 |
| MACD | 0.08 | -0.06 |
| Stochastic Oscillator | 75.91 | 11.00 |
Price Performance
Historical ComparisonAbout RNP Cohen & Steers REIT and Preferred and Income Fund Inc.
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.